Comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 vs 3m Syndrome 1 C2678312
Clinical comparison between 3 Methylcrotonyl Coa Carboxylase 1 Deficiency CN028786 and 3M Syndrome 1 for differential diagnosis and treatment planning.
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
A metabolic disorder affecting the processing of leucine, an amino acid. Symptoms may include developmental delay, low blood sugar, and feeding problems. Dietary restrictions and supplementation are typically used in management.
3m Syndrome 1 C2678312
A genetic disorder causing severe short stature with distinctive facial features and skeletal abnormalities. Management involves monitoring growth and addressing orthopedic or other associated concerns.
6 comparison axes
Onset
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
0-null
3m Syndrome 1 C2678312
0-0
Onset patterns differ
Severity
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
severe
3m Syndrome 1 C2678312
moderate
Different severity levels
Chronic
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
Chronic
3m Syndrome 1 C2678312
Chronic
Differing course
Communicable
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
No
3m Syndrome 1 C2678312
No
Different transmission
Body System
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
3m Syndrome 1 C2678312
musculoskeletal
Same/different system
Category
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
3m Syndrome 1 C2678312
genetic
Different category
Bottom line
3-methylcrotonyl-coa-carboxylase-1-deficiency-CN028786 and 3m-syndrome-1-C2678312 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 3m Syndrome 1 C2678312 | Discriminating power |
|---|---|---|---|
| Growth pattern | Short stature is not described; metabolic symptoms may predominate. | Severe short stature is a core described feature. | High |
| Metabolic symptoms | May include low blood sugar, feeding problems, and developmental delay. | These metabolic features are not described in the source. | High |
| Skeletal and facial findings | Distinctive skeletal or facial abnormalities are not described. | Distinctive facial features and skeletal abnormalities are described. | Moderate |
When to favor each condition
Choose 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 when
Unexplained low blood sugar or feeding difficulty
These features fit the supplied metabolic description better than 3M syndrome.
Moderate
Suspected leucine-processing disorder
The source specifically links the left condition to leucine metabolism.
High
Developmental delay with metabolic concern
Developmental delay is listed, but it is not specific and needs clinician interpretation.
Low
Choose 3m Syndrome 1 C2678312 when
Severe short stature from early life
Marked growth impairment is central to the supplied 3M syndrome description.
Moderate
Skeletal abnormalities needing orthopedic review
The source explicitly identifies orthopedic or associated concerns.
Moderate
Distinctive facial features with growth failure
This combination aligns with the genetic musculoskeletal description.
Moderate
How key tests differ
| Test | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 3m Syndrome 1 C2678312 | Interpretation |
|---|---|---|---|
| Metabolic biochemical testing | May support abnormal leucine-related metabolite processing; no cutoff is supplied. | No characteristic metabolic abnormality is described. | An abnormal result is not itself a diagnosis and requires specialist confirmation. |
| Growth and skeletal assessment | No specific growth or skeletal pattern is established here. | May document severe short stature and skeletal abnormalities. | Findings support clinical suspicion but do not prove the genetic diagnosis alone. |
| Genetic testing | May be used to confirm the suspected metabolic condition when clinically indicated. | May be used to confirm 3M syndrome 1 when clinically indicated. | Gene selection and interpretation belong to a qualified clinician or genetics service. |
Prognosis comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
- Outcome
- Outcome varies and is not quantified in the source; management commonly includes diet and supplementation.
- Factors
- Symptom severity, metabolic stability, feeding, and developmental course may matter.
3m Syndrome 1 C2678312
- Outcome
- Persistent short stature is expected, while overall prognosis is not quantified here.
- Factors
- Growth pattern and orthopedic or associated complications may influence course.
Time frame: Both are described as chronic; precise onset and long-term outcomes are not established.
Clinician interpretation is required because severity labels and sparse descriptions do not determine individual prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Metabolic decompensation | Low blood sugar and feeding problems may signal metabolic stress. Not described as a typical feature in the source. Exact triggers, frequency, and severity are not established here. |
| Growth impairment | Not identified as a defining complication in the supplied description. Severe short stature is described and requires growth monitoring. Adult height and treatment response are not provided. |
| Orthopedic problems | No specific orthopedic complication is described. Associated skeletal concerns may require monitoring or intervention. The type and severity of skeletal complications are not specified. |
Patient education highlights
- HighDifferent conditions
These conditions affect different systems and should not be treated as interchangeable diagnoses.
- HighWarning symptoms
For the metabolic condition, seek urgent care for poor feeding, lethargy, or suspected low blood sugar.
- MediumFollow-up
3M syndrome generally requires growth monitoring and attention to orthopedic or associated concerns.